About this Speaker
Susan K. Whoriskey, PhD
Biotechnology Executive, Technology Strategy & Business Development
Susan Whoriskey, PhD has served sequentially on the founding Executive
Teams of four biotech companies: TruCode, Moderna (MRNA), Momenta
Pharmaceuticals (MNTA) and Cubist Pharmaceuticals (CBST). TruCode is
privately held. Moderna pioneered mRNA technology for drug
development, is currently in Phase 3 clinical trials for a Covid-19 vaccine
and has numerous other candidates in clinical trials to treat other diseases.
Momenta received the first ever FDA approval for a generic version of a
complex mixture drug while transitioning the application of its technology
to novel drug development for unmet diseases and was sold to J & J in 2020
for $6.5B. Cubist received FDA approval for one of the first new classes of
antibiotics approved by the FDA in 50 years to treat multi-drug resistant S.
aureus and was sold to Merck in 2014 for $9.5B. As a member of the
Executive Teams, Dr. Whoriskey played key roles in foundation setting,
building teams, managing translation of academic inventions into
therapeutic modalities, overseeing intellectual property strategy,
completing venture capital financings, negotiating corporate partnerships,
completing IPOs and follow-on financings and achieving four FDA drug
approvals to date. She has been a consultant to Polaris Venture Partners
and an Entrepreneur in Residence at MIT. Dr. Whoriskey earned her BS
from UMass-Amherst and PhD from UCLA and was a Research Fellow in
Molecular Genetics at Harvard Medical School with a Nobel Prize winner.
She is an inventor on 50 patents & applications and a recipient of an
Honorary Doctorate in Biotechnology and Entrepreneurism from the
University of Ulster.